RenovoRx Reports Strong Q2 2025 Revenue Growth

RenovoRx ( (RNXT) ) has provided an announcement.

RenovoRx reported a commercial revenue of over $400,000 for the second quarter of 2025, highlighting strong market demand for its RenovoCath device. The company has expanded its customer base to thirteen cancer centers, including high-volume National Cancer Institute-designated centers, and has achieved this growth without a dedicated sales team. Additionally, the independent Data Monitoring Committee recommended continuing the pivotal Phase III TIGeR-PaC trial after a positive interim data review, indicating confidence in the trial’s potential outcome. RenovoRx plans to strategically expand its sales team to enhance market penetration in 2026.

The most recent analyst rating on (RNXT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.

Spark’s Take on RNXT Stock

According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.

RenovoRx’s overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company’s valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.

To see Spark’s full report on RNXT stock, click here.

More about RenovoRx

RenovoRx, Inc. is a life sciences company focused on developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device. The company operates within the medical technology industry, with a market focus on localized solid tumor drug-delivery options.

Average Trading Volume: 170,472

Technical Sentiment Signal: Buy

Current Market Cap: $40.23M

See more data about RNXT stock on TipRanks’ Stock Analysis page.